The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
April 29th 2024
Here's some of what is coming soon to NeurologyLive® this week.
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
James Leverenz, MD: Differentiating Lewy Body Dementia
October 24th 2019The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic laid out these challenges that he and his colleagues face in differentiating patients with Lewy body dementia from other dementia pathologies.
FDA Issues Warning Letter for CBD Products to Treat Alzheimer, Parkinson
October 24th 2019The agency sent a joint letter with the FTC to Rooted Apothecary LLC for claiming its CBD products can medically treat a number of conditions including Alzheimer disease and Parkinson disease. Since 2017, the FDA has issued more than 10 such letters.
Aducanumab Heads to the FDA After Biogen Analysis Proves Positive in Early Alzheimer Disease
October 22nd 2019After pulling the plug on trials in March 2019, Biogen has announced that an expanded analysis revealed significant positive results for aducanumab in patients with early Alzheimer disease.
Gait Speed Is a Relevant Marker of Functional Decline, Aging at Midlife
October 11th 2019The findings have implications for ongoing early intervention research in Alzheimer disease and dementia since significant functional and neurocognitive declines were evident in middle age adults based on gait speed assessments.
Sex-Specific Parameters May Improve MCI Diagnostic Errors
October 10th 2019The study unearthed a 20% diagnostic error rate with non-sex-specific parameters—10% false negatives in women and 10% false positives in men—which the authors found may be eliminated with gender-specific norms and cut scores.
Bernard Baumel, MD: Evaluating Stem Cells in Alzheimer Disease
October 4th 2019Bernard Baumel, MD, and colleagues at the University of Miami have recently launched a clinical trial to examine the safety and efficacy of multiple doses of human mesenchymal stem cells in patients with Alzheimer disease.
World Alzheimer Day 2019: Key Takeaways From Leaders in Alzheimer Disease and Dementia
In recognition of World Alzheimer Day, experts in Alzheimer disease and dementia share insight from the latest Alzheimer Disease International's yearly World Alzheimer Report.
Elenbecestat Trials in Early Alzheimer Disease Terminated for Poor Risk-Benefit Profile
September 19th 2019The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.
Elenbecestat Trials in Early Alzheimer Disease Terminated for Poor Risk-Benefit Profile
September 13th 2019The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.
Can Transcranial Electromagnetic Treatment Turn the Tide in Alzheimer Disease?
September 9th 2019The founder and CEO of NeuroEM Therapeutics discussed the potential of transcranial electromagnetic treatment and shared insight into the advantages it may hold over the traditional treatment route.
Transcranial Electromagnetic Treatment Shows Promise for Alzheimer Disease
September 5th 2019The founder and CEO of NeuroEM Therapeutics discussed the potential of transcranial electromagnetic treatment, or TEMT, in treating patients with Alzheimer disease, with the hope of reversing cognitive impairment.
Parkinson Linked to Similar Cerebrovascular Risk Factors for Alzheimer
September 4th 2019A number of cerebrovascular risk factors found to be associated with a subsequent diagnosis of Alzheimer disease also showed a high association with a diagnosis of Parkinson disease, pressing the impetus for controlling these modifiable factors.